Emocha, one of nine graduates of the first class of startups from the DreamIt Health Baltimore accelerator, announced at Demo Day on April 30 that it’s opening an investment round this summer.
The mobile health platform is already being used in three separate pilot programs to allow physicians and clinicians based at health organizations to monitor patients’ symptoms, recovery and rehabilitation from a variety of diseases via smartphone.
Invented by medical experts at the Johns Hopkins University in 2008, the emocha mobile platform is HIPAA-compliant and is able to capture data from patients suffering from 10 different diseases, including tuberculosis and multidrug-resistant tuberculosis.
As emocha CEO Sebastian Seiguer explained at Demo Day, emocha will soon be in use by the state government of South Africa in that country’s efforts against multidrug-resistant tuberculosis:
- More than 10,000 healthcare workers and 2,500 primary care clinics in South Africa will be equipped with the emocha platform.
- The goal, as Seiguer explained, is to use emocha so that notifications and alerts are sent to tracing teams in South Africa chasing down outbreaks of multidrug-resistant tuberculosis, as well as to patients and clinics, so that people diagnosed with the disease will be able to start receiving care at clinics within five days of the initial diagnosis.